{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:51:00Z","timestamp":1791669060471,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.nucmedbio.2024.108944","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T03:00:12Z","timestamp":1722394812000},"page":"108944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Preclinical evaluation of [225Ac]Ac-crown-TATE \u2013 An alpha-emitting radiopharmaceutical for neuroendocrine tumors"],"prefix":"10.1016","volume":"138-139","author":[{"given":"Aidan","family":"Ingham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Wharton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Koniar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Merkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathiya","family":"Sekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Osooly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rodr\u00edguez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"B\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Schaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2024.108944_bb0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1053\/j.seminoncol.2018.07.001","article-title":"Epidemiologic trends in neuroendocrine tumors: an examination of incidence rates and survival of specific patient subgroups over the past 20 years","volume":"45","author":"Sackstein","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/cancers14010129","article-title":"Peptide receptor radionuclide therapy targeting the somatostatin receptor: basic principles","volume":"14","author":"Ahmadi Bidakhvidi","year":"2021","journal-title":"Clinical Applications and Optimization Strategies Cancers (Basel)"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0020","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225 Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate Cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0030","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0035","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2021.39.15_suppl.4112","article-title":"Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors","volume":"39","author":"Strosberg","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0040","article-title":"Safety and therapeutic efficacy of 225Ac-DOTATATE targeted alpha therapy in metastatic Gastroenteropancreatic neuroendocrine tumors stable or refractory to 177Lu-DOTATATE PRRT","volume":"61","author":"Bal","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0045","article-title":"Early results of 225Ac-DOTATATE targeted alpha therapy in metastatic Gastroenteropancreatic neuroendocrine tumors: first clinical experience on safety and efficacy","volume":"60","author":"Ballal","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0050","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.2967\/jnumed.114.138347","article-title":"Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225 ac for \u03b1-particle Radioimmunotherapy of Cancer","volume":"55","author":"Maguire","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0055","doi-asserted-by":"crossref","first-page":"11435","DOI":"10.1002\/chem.202002999","article-title":"Synthesis and evaluation of a macrocyclic Actinium-225 Chelator, quality control and in vivo evaluation of 225Ac-crown-\u03b1MSH peptide. Chemistry \u2013 a","volume":"26","author":"Yang","year":"2020","journal-title":"European Journal"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0060","doi-asserted-by":"crossref","first-page":"14712","DOI":"10.1002\/anie.201709532","article-title":"An eighteen-membered macrocyclic ligand for Actinium-225 targeted alpha therapy","volume":"56","author":"Thiele","year":"2017","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0065","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1021\/acs.bioconjchem.0c00171","article-title":"225 ac-H 4 py4pa for targeted alpha therapy","volume":"32","author":"Li","year":"2021","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0070","doi-asserted-by":"crossref","unstructured":"Wharton L, Yang H, Jaraquemada-Pel\u00e1ez M de G, Merkens H, Engudar G, Ingham A, et al. Rearmed bifunctional chelating ligand for 225 ac\/ 155 Tb precision-guided Theranostic radiopharmaceuticalsH 4 noneunpaX. J Med Chem 2023;66:13705\u201330. doi:https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01151.","DOI":"10.1021\/acs.jmedchem.3c01151"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0075","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.semnuclmed.2020.02.004","article-title":"225Ac-PSMA-617 for therapy of prostate Cancer","volume":"50","author":"Kratochwil","year":"2020","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41181-024-00239-1","article-title":"Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives","volume":"9","author":"Hooijman","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0085","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2967\/jnumed.122.264707","article-title":"225 Ac-MACROPATATE: a novel \u03b1-particle peptide receptor radionuclide therapy for neuroendocrine tumors","volume":"64","author":"King","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0090","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2967\/jnumed.118.219592","article-title":"A single dose of 225 ac-RPS-074 induces a complete tumor response in an LNCaP xenograft model","volume":"60","author":"Kelly","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0095","doi-asserted-by":"crossref","first-page":"11435","DOI":"10.1002\/chem.202002999","article-title":"Synthesis and evaluation of a macrocyclic Actinium-225 Chelator, quality control and in vivo evaluation of 225 ac-crown-\u03b1MSH peptide. Chemistry \u2013 a","volume":"26","author":"Yang","year":"2020","journal-title":"European Journal"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0100","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.3390\/molecules28073155","article-title":"Preclinical evaluation of [155\/161Tb]Tb-crown-TATE\u2014A novel SPECT imaging Theranostic agent targeting neuroendocrine Tumours","volume":"28","author":"Wharton","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0105","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.nucmedbio.2018.08.001","article-title":"Effects of adding an albumin binder chain on [177Lu]Lu-DOTATATE","volume":"66","author":"Rousseau","year":"2018","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0110","doi-asserted-by":"crossref","first-page":"12156","DOI":"10.1021\/acs.inorgchem.0c01081","article-title":"232 Th-spallation-produced 225 ac with reduced 227 ac content","volume":"59","author":"Robertson","year":"2020","journal-title":"Inorg Chem"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/instruments3010018","article-title":"Design of a Thorium Metal Target for 225Ac production at TRIUMF","volume":"3","author":"Robertson","year":"2019","journal-title":"Instruments"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1023\/B:JRNC.0000030956.61947.c5","article-title":"The hydrolysis of actinium","volume":"261","author":"Zieli\u0144ska","year":"2004","journal-title":"J Radioanal Nucl Chem"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0125","doi-asserted-by":"crossref","unstructured":"Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD Pamphlet No. 21: a generalized Schema for radiopharmaceutical dosimetry\u2014standardization of nomenclature. J Nucl Med 2009;50:477\u201384. doi:https:\/\/doi.org\/10.2967\/jnumed.108.056036.","DOI":"10.2967\/jnumed.108.056036"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0130","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40658-023-00564-5","article-title":"A GATE simulation study for dosimetry in cancer cell and micrometastasis from the 225Ac decay chain","volume":"10","author":"Koniar","year":"2023","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0135","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41586-020-2649-2","article-title":"Array programming with NumPy","volume":"585","author":"Harris","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0140","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.21105\/joss.01317","article-title":"Lifelines: survival analysis in Python","volume":"4","author":"Davidson-Pilon","year":"2019","journal-title":"J Open Source Softw"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0145","doi-asserted-by":"crossref","first-page":"E1107","DOI":"10.1152\/ajpendo.00207.2012","article-title":"SSTR2 is the functionally dominant somatostatin receptor in human pancreatic \u03b2- and \u03b1-cells","volume":"303","author":"Kailey","year":"2012","journal-title":"American Journal of Physiology-Endocrinology and Metabolism"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0150","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/1874471011666180423120707","article-title":"In vivo evaluation of free and chelated accelerator-produced actinium- 225 - radiation dosimetry and toxicity results","volume":"11","author":"Jiang","year":"2018","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.nucmedbio.2024.108944_bb0155","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2967\/jnumed.120.250738","article-title":"177 Lu-labeled albumin-binder\u2013conjugated PSMA-targeting agents with extremely high tumor uptake and enhanced tumor-to-kidney absorbed dose ratio","volume":"62","author":"Kuo","year":"2021","journal-title":"J Nucl Med"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805124000702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805124000702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T22:47:42Z","timestamp":1734648462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805124000702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":31,"alternative-id":["S0969805124000702"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108944","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of [225Ac]Ac-crown-TATE \u2013 An alpha-emitting radiopharmaceutical for neuroendocrine tumors","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108944"}}